After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...

James Foster’s legendary half-century run at Charles River Laboratories is coming to an end. After more than 30 years as ...

Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

Spiro Medical, which debuted last year, reeled in $67 million in series A funding it plans to use to develop its novel ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital ...

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

Tessera Therapeutics is planning to lay off 90 employees, the Flagship-founded biotech has warned. | Tessera Therapeutics is ...

Impella, which J&J touts as the world’s smallest heart pump, has a range of devices used for various heart conditions. Lexeo ...

EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...

In return for $10 million upfront, Foresee sold the global rights for its MMP-12 inhibitor programs to Primevera Therapeutics ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...